Startups doing autonomous scientific experimentation (self-driving labs)
August 26 at 09:37 · $0.105 total
- Kebotix — AI-driven materials discovery platform that runs closed-loop robotic experiments for chemicals and polymers.
Why it fits: Harvard spin-out; raised seed/Series A from deep-tech funds; active industrial partnerships in materials.
- LabGenius — Autonomous antibody discovery platform (EVA) combining machine learning with robotic wet-lab testing to evolve therapeutic proteins.
Why it fits: Series B stage; multi-target pharma collaborations validate closed-loop protein engineering.
- Chemify — Building programmable chemistry infrastructure (“chemputation”) to automate molecular synthesis and discovery.
Why it fits: Founded by Lee Cronin; significant UK/VC backing; early but high-signal effort to make chemistry a programmable, autonomous discipline.
- Atinary Technologies — AI/ML platform that turns lab instruments into self-driving labs via real-time experiment optimization.
Why it fits: EPFL spin-out; deployed with chemicals and materials corporates; early revenue and strong technical team.
- Arctoris — Robotic laboratory-as-a-service for automated drug discovery experiments, generating reproducible, high-quality data.
Why it fits: Series A; partnerships with biotech/pharma in oncology and CNS; demonstrates autonomous experimentation as a service.
- Strateos — Cloud-based robotic lab platform for remote, programmable experimentation across biology and chemistry.
Why it fits: Formed from Transcriptic/3Scan merger; enterprise and government contracts; proven cloud-lab model.
- Emerald Cloud Lab — Cloud laboratory that lets scientists run automated experiments remotely using code.
Why it fits: Used by academic centers and biotech; established but still expanding autonomy/AI features; key infrastructure for self-driving labs.
- Synthace — Experiment design and automation software (“Antha”) enabling reproducible, data-rich biological workflows.
Why it fits: Early-ish company with pharma/ag partnerships; its software layer is a critical enabler for closing the loop in biology labs.
- Odyssey Therapeutics — Bio company building a self-driving drug discovery engine spanning AI, biology, chemistry, and automation.
Why it fits: Founded 2020; large Series C; rapid pipeline growth; less-known than Insitro but strong internal autonomy stack.
- Insitro — AI-driven drug discovery with an in-house automated laboratory generating high-content data for machine learning.
Why it fits: Raised >$600M; partnerships with Gilead/BMS; late-stage but a benchmark for autonomous biology at scale.
White-space gaps noticed while sourcing:
- Formulation and complex-mixture self-driving labs — most startups target drug discovery or advanced materials; food, agchem, personal care, and consumer products with sensory/rheological properties remain underserved.
- General-purpose robotic manipulation that retrofits legacy instruments — current platforms often require standardized liquid handling or purpose-built hardware; a layer that handles messy, real-world lab operations (powders, viscous fluids, heterogeneous samples) on existing instruments would unlock much broader adoption.
- Arctoris — Operates a robotic, remotely accessible drug-discovery laboratory that executes and analyzes experiments with software-controlled workflows; fits as an early-stage company built explicitly around autonomous, data-generating wet-lab experimentation, with venture backing and pharmaceutical partnerships.
- Atinary Technologies — Provides AI-driven experiment-design and optimization software that connects to laboratory instruments to run closed-loop materials and chemistry experiments; fits as an early European startup focused directly on self-driving laboratory workflows rather than only predictive modeling.
- Kebotix — Combines machine learning, robotics, and automated synthesis/testing to discover advanced materials; fits through its “autonomous materials discovery” model and its history of government funding, research collaborations, and commercial materials programs.
- Chemify — Develops software and automated chemistry infrastructure intended to design and synthesize molecules with minimal human intervention; fits as a relatively young, well-funded company targeting autonomous chemical discovery and synthesis.
- Adaptyv Bio — Uses automated microfluidic experimentation, high-throughput protein engineering, and machine learning to optimize biological molecules; fits as an early company whose core loop is AI-guided design, robotic testing, and iterative biological learning.
- Aether Biomachines — Builds robotic and computational systems for automating biological experimentation, including cell and protein engineering workflows; fits as an early-stage “lab-in-a-box” style company aimed at making experimental biology more autonomous.
- LabGenius — Runs automated protein-engineering campaigns in which machine learning proposes antibody variants and robotic systems build and test them; fits as a proven example of a closed-loop self-driving biology platform, supported by substantial venture funding and pharma collaborations.
- Strateos — Provides cloud laboratories with remotely programmable robotic equipment for chemistry and biology experiments; fits as enabling infrastructure for autonomous experimentation, with a substantial installed platform and usage by biotech, pharmaceutical, and academic customers.
- Emerald Cloud Lab — Offers a fully automated, remotely operated laboratory in which software can specify, execute, and monitor complex experiments; fits as a commercial cloud-lab platform with real operational scale, even though it is more infrastructure-oriented than a single-domain discovery startup.
- Synthace — Provides software for programmatically designing, orchestrating, and analyzing automated biology experiments across laboratory instruments; fits as the control and data layer for self-driving labs, with enterprise deployments and partnerships in industrial biology and biopharma.
White-space gaps noticed:
- Autonomous experimentation for real-world manufacturing conditions: Many platforms optimize molecules or materials at bench scale, but fewer close the loop across pilot-scale synthesis, process economics, impurity analysis, and manufacturability.
- Self-driving labs for complex, poorly standardized biology: Protein engineering is relatively automation-friendly; there is still room for robust autonomous systems handling primary cells, organoids, microbiomes, animal-derived samples, and other variable biological models.